Lonapegsomatropin

Lonapegsomatropin, sold under the brand name Skytrofa, is a human growth hormone used for the treatment of growth hormone deficiency.[1] Lonapegsomatropin is a prodrug of somatropin.[1]

Lonapegsomatropin
Clinical data
Trade namesSkytrofa
Other namesLonapegsomatropin-tcgd; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598
License data
Routes of
administration		Subcutaneous injection
Drug classGrowth hormone receptor agonist
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
PubChem SID
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC1051H1627N269O317S9[C2H4O]4n

Lonapegsomatropin was approved for medical use in the United States in August 2021.[1][2][4]

Medical uses

Lonapegsomatropin is a growth hormone therapy indicated to treat growth hormone deficiency.[1][3]

References
  1. "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Retrieved 30 September 2021.
  2. "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 25 August 2021.
  3. "Lonapegsomatropin Ascendis Pharma EPAR". European Medicines Agency. 10 November 2021. Retrieved 16 March 2022.
  4. "Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of Skytrofa (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency". Ascendis Pharma (Press release). 25 August 2021. Retrieved 25 August 2021.

Further reading
  • "Lonapegsomatropin". Drug Information Portal. U.S. National Library of Medicine.
  • Clinical trial number NCT02781727 for "A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.